Control of methicillin resistant Staphylococcus aureus infection utilizing a novel immunostimulatory peptide

Tamsin R. Sheen, Courtney K. Cavaco, Celia M. Ebrahimi, Marilyn L. Thoman, Sam D. Sanderson, Edward L. Morgan, Kelly S. Doran

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

The emergence of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) is a serious health concern worldwide that requires new therapeutic approaches that extend beyond the development and use of new antibiotics. In this study, a conformationally biased, response-selective agonist of human C5a, known as EP67, was used to induce host innate immunity as a therapeutic method of reducing CA-MRSA infections. Using a murine model of dermonecrosis we show that EP67 treatment effectively limits CA-MRSA infection by promoting cytokine synthesis and neutrophil influx. In contrast, EP67 was ineffective in reducing lesion formation in C5a receptor (CD88-/-) knockout mice, indicating that EP67 activates host innate immunity by engagement of CD88 bearing cells. These results suggest that EP67 may serve as a novel immunotherapeutic for prevention and treatment of CA-MRSA dermal infection.

Original languageEnglish (US)
Pages (from-to)9-13
Number of pages5
JournalVaccine
Volume30
Issue number1
DOIs
StatePublished - Dec 9 2011

Keywords

  • C5a agonist
  • CA-MRSA
  • EP67
  • Innate immunity
  • PMN
  • Staphylococcus aureus

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Control of methicillin resistant Staphylococcus aureus infection utilizing a novel immunostimulatory peptide'. Together they form a unique fingerprint.

  • Cite this

    Sheen, T. R., Cavaco, C. K., Ebrahimi, C. M., Thoman, M. L., Sanderson, S. D., Morgan, E. L., & Doran, K. S. (2011). Control of methicillin resistant Staphylococcus aureus infection utilizing a novel immunostimulatory peptide. Vaccine, 30(1), 9-13. https://doi.org/10.1016/j.vaccine.2011.10.054